Genmab — Oktober 2019
-
God morgen.

-
ALL: Ein aussichtsreicher Antikörper https://healthcare-in-europe.com/de/news/all-ein-aussichtsreicher-antikoerper.html
-
Thanks E L. Great results. 50% of cancer cells were killed after dara treatment

-
Sorry wrong. 50% of patients were cancer free after dara treatment
-
Mind you; pre-clinical . This is the article in blood that is linked to in full (we saw the abstract here before)
https://sci-hub.tw/10.1182/blood.2019000904 -
in the DELPHINUS trial Dara is used with chemo. https://clinicaltrials.gov/ct2/show/NCT03384654
-
Jeps Bulder. Det er dyremodeller.
-
Nu har jeg det nok med at være småparanoid, men jeg tænker, at når Marshall Wace LLP annoncerer øget shorting i Genmab, (som dog stadigvæk er er under deres satsning pr. 15/8) så et det udelukkende med det formål at skabe utryghed hos de aktionærer, der ikke sætter sig dybere ind i Genmabs historik, hvor de gode nyheder har stået i kø i længere tid. Når de på trods af ovennævnte, formår at få kursen til at falde nogelunde markant, så må det bero på samarbejde og måske shorthandel? eller......
-
Danske hæver fra 1.570 til 1.650.
-
Doublo. Marshall er short over en bred kam i biotek. Der er ikke så meget mystik i det.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind